Holger N. Reithinger

Operates as an investment company that specializes in private equity and infrastructure

Provides bio-pharmaceutical research development services

Develops drugs for cancer treatment

Develops, manufactures, and markets separation technology used for filtration, purification and storage of chemicals, and other liquids and samples

Engages in the clinical research and development of novel drugs against cancer & autoimmune diseases with focus on personalized immunotherapies

Engages in the development and commercialization of in vitro diagnostic tests for cancer

Discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases

Develops and commercializes novel pain management therapies

GLSV is an active, long-term manager which aims to create and build value exclusively in life science companies in the UK, Switzerland, German-speaking countries and the US. They invest in many areas of the life sciences including the cancer, immunology, vaccines, biopharmaceuticals, indication-specific genomics, genomics tools, diagnostics, medical devices, healthcare services and cardiovascular areas. The firm primarily invests in early-stage companies that operate in significant markets with considerable upside potential, as well as in later-stage companies, including buyouts, which meet their investment in their home markets, GLSV is the lead investor or an active co-investor, while outside of their home markets they only act as a knowledgeable co-investor.